Tagged with pharmaceuticals

Switzerland A. Vogel CEO Dr Andy Suter outlines the Swiss herbal medicine market leader’s expansion in recent years, why it is prioritising R&D more than ever, and how the COVID-19 pandemic has created a renewed focus on phytopharmaceuticals and preventive medicine.   There is a segment of people looking to take…

Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production.   2020 was defined by an increase in demand for dietary supplements because…

Switzerland Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be an inflection point for phytopharma, and what keeps him motivated after 22 years at the firm.   COVID has led…

Norway Jan Børge Jakobsen, managing director of Bayer Norway, shares how he came to lead Bayer’s Norwegian affiliate after 30 years within the Norwegian pharma industry; Norway’s innovation capabilities in radiopharmaceuticals; and his excitement surrounding Bayer’s portfolio and upcoming product launches in Norway.   Through the acquisition and integration of Algeta,…

Spain Damaso Molero, general manager of 3P Biopharmaceuticals, a leading Spanish CDMO, highlights the growth of the company and the need to continuously increase capacity to meet market demands. Furthermore, he touches on the innovation ecosystem in Spain and how 3P works with clients, rather than for them, to achieve long-term…

Cannabis Founded in 1998, GW Pharmaceuticals is a true pioneer in cannabinoid medicines and the only pharmaceutical company with a license to cultivate cannabis in the UK. “While people were wary of cannabis, they became very aware that it was treating patients with severe conditions, where other medicines had either failed…

Canada Jaiveer Singh, CEO of Mint Pharmaceuticals explains the company’s business model and how it fits the characteristics of the Canadian market on the tenth anniversary of the company. He further highlights how Mint’s portfolio of boutique generics is sure to grow over the coming years to meet the specific needs…

Canada Ian Jacobson, CEO of Juno Pharmaceuticals, presents the company’s business model of in-licensing and repurposing generic products. He highlights the successful development of the company’s affiliates in Australia, the UK and South Africa, and his plans to refocus efforts on the Canadian market in the near future, aiming to launch…

Canada John London, CEO at Nuvo Pharmaceuticals Inc., explains how he and his partners turned the Canadian company from insolvency into a profitable enterprise with FDA approved products that are being marketed around the world. He further talks opportunities in the topical pain management market and how Nuvo Pharmaceuticals will enhance…

Taiwan Chin Chun Lin, chairman of Taiwan Leader Biotech Corp., discusses the importance of herbal medicine for preventive healthcare, and shares valuable insights into Taiwan Leader Biotech Corp., a leading company in medicinal fungus, that established brand recognition through balancing social, economic and environmental perspectives while promoting the importance of the…

Switzerland With a recent clinical trial showing one of Bioforce’s Echinacea products to be non-inferior to the gold standard allopathic treatment Tamiflu, CEO Peter Gmünder is working to continue the work of Swiss phytopharmaceuticals pioneer Alfred Vogel by providing the highest quality natural remedies made using only fresh herbs if possible.…

Pharma Do phenomenons such as Brexit and the Trump election victory mean trouble for the pharma industry or are you more optimistic? Take the PharmaBoardroom poll on the pharma industry in 2017 and stay tuned for the results! Create your own user feedback survey